4//SEC Filing
Chione Ltd 4
Accession 0001213900-23-049014
CIK 0001781174other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 6:33 PM ET
Size
17.6 KB
Accession
0001213900-23-049014
Insider Transaction Report
Form 4
Chione Ltd
10% Owner
Transactions
- Sale
Common Stock
2023-06-12$12.34/sh−2,000$24,680→ 3,854,597 total - Sale
Common Stock
2023-06-13$12.30/sh−3,000$36,900→ 3,851,597 total - Sale
Common Stock
2023-06-14$12.13/sh−893$10,832→ 3,850,704 total
Czernik Marcin
10% Owner
Transactions
- Sale
Common Stock
2023-06-14$12.13/sh−893$10,832→ 3,850,704 total - Sale
Common Stock
2023-06-13$12.30/sh−3,000$36,900→ 3,851,597 total - Sale
Common Stock
2023-06-12$12.34/sh−2,000$24,680→ 3,854,597 total
Hadjimichael Andreas
10% Owner
Transactions
- Sale
Common Stock
2023-06-12$12.34/sh−2,000$24,680→ 3,854,597 total - Sale
Common Stock
2023-06-13$12.30/sh−3,000$36,900→ 3,851,597 total - Sale
Common Stock
2023-06-14$12.13/sh−893$10,832→ 3,850,704 total
Nikolaou Anastasis
10% Owner
Transactions
- Sale
Common Stock
2023-06-12$12.34/sh−2,000$24,680→ 3,854,597 total - Sale
Common Stock
2023-06-13$12.30/sh−3,000$36,900→ 3,851,597 total - Sale
Common Stock
2023-06-14$12.13/sh−893$10,832→ 3,850,704 total
Smolokowski Wiaczeslaw
10% Owner
Transactions
- Sale
Common Stock
2023-06-12$12.34/sh−2,000$24,680→ 3,854,597 total - Sale
Common Stock
2023-06-13$12.30/sh−3,000$36,900→ 3,851,597 total - Sale
Common Stock
2023-06-14$12.13/sh−893$10,832→ 3,850,704 total
Footnotes (5)
- [F1]The prices reported in Column 4 are weighted average prices. The 2,000 shares referred to in the first row of Column 4 were sold at prices ranging from $12.165 to $12.49, inclusive. The 3,000 shares referred to in the second row of Column 4 were sold at prices ranging from $12.03 to $12.55, inclusive. The 893 shares referred to in the third row of Column 4 were sold at prices ranging from $12.01 T0 $12.47, inclusive.
- [F2]The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.
- [F3]Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione.
- [F4]Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- [F5]Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
IncorporatedCyprus
Related Parties
1- filerCIK 0001590232
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 6:33 PM ET
- Size
- 17.6 KB